Literature DB >> 10704939

Involvement of apoptosis in mitomycin C hypersensitivity of Chinese hamster cell mutants.

E Papouli1, C Lafon, A Valette, M Z Zdzienicka, M Defais, F Larminat.   

Abstract

To elucidate the mechanisms of the mammalian cell defense against cross-linking agents, we studied previously cellular responses to mitomycin C (MMC) treatment in two MMC-hypersensitive hamster cell mutants' V-H4 and V-C8, as well as their parental cell line V79. In the present report, we investigated whether alterations in cell cycle checkpoints and induction of apoptosis could be responsible for the MMC hypersensitivity of the V-H4 and V-C8 mutant cell lines. First, we found that parental and mutant cells exhibited similar cell cycle responses to MMC concentrations of equivalent cytotoxicity, arguing against a defective cell cycle checkpoint in hypersensitive cell lines. In contrast, we showed that mutant cells underwent greater levels of apoptosis following MMC treatment than parental cells. These findings indicate that increased induction of apoptosis contributes to the hypersensitivity of V-H4 and V-C8 cells to the growth inhibitory effect of MMC. This differential apoptotic response was observed with both equimolar and equitoxic MMC doses and was specific to the cross-linking agent MMC, suggesting that control of the apoptotic process is altered in both MMC-hypersensitive mutants. The defective genes in V-H4 and V-C8 cells would then function in the regulation of an apoptotic pathway triggered by MMC-induced damage and independent of p53-mediated transcription.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704939     DOI: 10.1016/s0006-2952(00)00234-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions.

Authors:  Maria Kraakman-van der Zwet; Wilhelmina J I Overkamp; Rebecca E E van Lange; Jeroen Essers; Annemarie van Duijn-Goedhart; Ingrid Wiggers; Srividya Swaminathan; Paul P W van Buul; Abdellatif Errami; Raoul T L Tan; Nicolaas G J Jaspers; Shyam K Sharan; Roland Kanaar; Malgorzata Z Zdzienicka
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

2.  The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.

Authors:  Joseph A De Soto; Xianyan Wang; Yohei Tominaga; Rui-Hong Wang; Liu Cao; Wenhui Qiao; Cuiling Li; Xiaoling Xu; Amanda P Skoumbourdis; Sheila A Prindiville; Craig J Thomas; Chu-Xia Deng
Journal:  Int J Biol Sci       Date:  2006-06-10       Impact factor: 6.580

3.  Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant.

Authors:  M Ottey; S-Y Han; T Druck; B L Barnoski; K A McCorkell; C M Croce; C Raventos-Suarez; C R Fairchild; Y Wang; K Huebner
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.